These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24316794)

  • 1. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
    Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
    Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
    Unland R; Clemens D; Heinicke U; Potratz JC; Hotfilder M; Fulda S; Wardelmann E; Frühwald MC; Dirksen U
    Anticancer Drugs; 2015 Sep; 26(8):843-51. PubMed ID: 26053276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
    Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
    Boehme KA; Nitsch J; Riester R; Handgretinger R; Schleicher SB; Kluba T; Traub F
    Int J Oncol; 2016 Nov; 49(5):2135-2146. PubMed ID: 27665785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
    Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
    Zhou Z; Guan H; Duan X; Kleinerman ES
    Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of adriamycin cytotoxicity by sodium butyrate involves hTERT downmodulation-mediated apoptosis in human uterine cancer cells.
    Yu M; Kong H; Zhao Y; Sun X; Zheng Z; Yang C; Zhu Y
    Mol Carcinog; 2014 Jul; 53(7):505-13. PubMed ID: 23359532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
    Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
    Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.
    Mueller SK; Altvater B; Chen C; Kailayangiri S; Ahlmann M; Dirksen U; Juergens H; Rossig C
    Oncol Rep; 2013 Jun; 29(6):2348-54. PubMed ID: 23525469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.
    Kars MD; Işeri OD; Ural AU; Gündüz U
    Anticancer Res; 2007; 27(6B):4031-7. PubMed ID: 18225567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells.
    Li L; Sun Y; Liu J; Wu X; Chen L; Ma L; Wu P
    BMC Biochem; 2015 Jan; 16():2. PubMed ID: 25592494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.